Appendix 4E and Annual Report

• Percheron reported a full-year loss of $4,791,745, down 68% from the previous year
• The company successfully completed a phase I clinical trial of HMBD-002, showing excellent safety and tolerability
• HMBD-002 has been designated 'minperstobart' by the World Health Organization
• Percheron is preparing for a phase II clinical trial of HMBD-002 in the second half of CY2026
• Dr. Michael Baker has been appointed as the new CEO of Percheron

Percheron Therapeutics Limited reported a full-year loss of $4,791,745 for the year ended 30 June 2026, a 68% decrease from the previous year. The loss was attributed to research and development costs, including the manufacture of clinical trial materials for HMBD-002, a monoclonal antibody targeting VISTA. The company successfully completed a phase I clinical trial of HMBD-002, which demonstrated excellent safety and tolerability, both as monotherapy and in combination with pembrolizumab. The World Health Organization designated HMBD-002 as 'minperstobart', indicating its potential as a mid-clinical stage asset. Percheron is preparing for a phase II clinical trial of HMBD-002, aiming to commence in the second half of CY2026. The company also announced the appointment of Dr. Michael Baker as the new CEO, effective 1 September 2026.

Percheron expects to commence a phase II clinical trial of HMBD-002 in the second half of CY2026.

Percheron is optimistic about the future of HMBD-002, aiming to demonstrate its efficacy through upcoming clinical trials and partnerships.